Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Pfiz­er has se­cured an FDA ap­proval for etrasi­mod in mod­er­ate to se­vere ul­cer­a­tive col­i­tis. It’s the sec­ond sphin­go­sine-1-phos­phate (S1P) drug to ar­rive on the UC mar­ket af­ter Bris­tol My­ers Squibb’s Zeposia.

Etrasi­mod, to be mar­ket­ed as Vel­sip­i­ty, is an oral S1P re­cep­tor mod­u­la­tor to be tak­en once a day. While it will com­pete with Zeposia, Pfiz­er will al­so have to dis­tin­guish the drug from a host of oth­er treat­ments, in­clud­ing steroids and bi­o­log­ics. Pfiz­er has set a whole­sale ac­qui­si­tion cost of $6,164 for a 30-day bot­tle, or $75,000 per year, which Ever­core ISI not­ed is mid­dle of the pack among ex­ist­ing op­tions. A spok­ersper­son said the drug will be avail­able in the US start­ing in late No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER